Curis to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
Curis Inc. (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), an oral IRAK4 inhibitor, has announced its plans to release second quarter 2024 financial and operating results on August 1, 2024, at 8:00 a.m. ET. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results. Interested parties can join the call by dialing (800)-836-8184 from the US or (646)-357-8785 from other locations. A live audio webcast will be available on the investor section of the Curis website, with a replay accessible later at www.curis.com.
Curis Inc. (NASDAQ: CRIS), un'azienda biotecnologica che sviluppa emavusertib (CA-4948), un inibitore orale dell'IRAK4, ha annunciato i suoi piani per rilasciare i risultati finanziari e operativi del secondo trimestre 2024 il 1 agosto 2024, alle 8:00 ET. L'azienda organizzerà una chiamata e un webcast alle 8:30 ET dello stesso giorno per discutere i risultati. Le parti interessate possono partecipare alla chiamata componendo il numero (800)-836-8184 dagli Stati Uniti o il (646)-357-8785 da altre località. Un webcast audio dal vivo sarà disponibile nella sezione investitori del sito web di Curis, con una registrazione accessibile successivamente su www.curis.com.
Curis Inc. (NASDAQ: CRIS), una empresa biotecnológica que desarrolla emavusertib (CA-4948), un inhibidor oral de IRAK4, ha anunciado sus planes para divulgar los resultados financieros y operativos del segundo trimestre de 2024 el 1 de agosto de 2024, a las 8:00 a.m. ET. La compañía llevará a cabo una llamada y un webcast a las 8:30 a.m. ET el mismo día para discutir los resultados. Las partes interesadas pueden unirse a la llamada marcando (800)-836-8184 desde EE.UU. o (646)-357-8785 desde otras ubicaciones. Un webcast de audio en vivo estará disponible en la sección de inversores del sitio web de Curis, con una reproducción accesible más tarde en www.curis.com.
Curis Inc. (NASDAQ: CRIS)는 구강 IRAK4 억제제인 emavusertib (CA-4948)를 개발하는 생명공학 회사로, 2024년 2분기 재무 및 운영 결과를 2024년 8월 1일 오전 8시 (ET)에 발표할 계획이라고 밝혔습니다. 회사는 같은 날 오전 8시 30분 (ET)에 결과에 대한 논의를 위해 컨퍼런스 콜 및 웨비나를 개최할 예정입니다. 관심 있는 분들은 미국에서 (800)-836-8184 또는 다른 지역에서 (646)-357-8785로 전화를 걸어 참여할 수 있습니다. Curis 웹사이트의 투자자 섹션에서 라이브 오디오 웨비나를 이용할 수 있으며, 이후 www.curis.com에서 재생할 수 있습니다.
Curis Inc. (NASDAQ: CRIS), une entreprise de biotechnologie développant l'emavusertib (CA-4948), un inhibiteur oral de l'IRAK4, a annoncé ses plans pour publier les résultats financiers et opérationnels du deuxième trimestre 2024 le 1er août 2024 à 8h00 (ET). L'entreprise organisera une conférence téléphonique et un webinaire à 8h30 (ET) le même jour pour discuter des résultats. Les parties intéressées peuvent rejoindre l'appel en composant le (800)-836-8184 depuis les États-Unis ou le (646)-357-8785 depuis d'autres localités. Un webinaire audio en direct sera disponible dans la section investisseurs du site Web de Curis, avec un enregistrement accessible ultérieurement sur www.curis.com.
Curis Inc. (NASDAQ: CRIS), ein biotechnologisches Unternehmen, das emavusertib (CA-4948), einen oralen IRAK4-Inhibitor, entwickelt, hat seine Pläne bekannt gegeben, die finanziellen und betrieblichen Ergebnisse für das zweite Quartal 2024 am 1. August 2024 um 8:00 Uhr ET bekannt zu geben. Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und ein Webinar abhalten, um die Ergebnisse zu besprechen. Interessierte Parteien können an dem Anruf teilnehmen, indem sie (800)-836-8184 aus den USA oder (646)-357-8785 aus anderen Ländern wählen. Ein Live-Audio-Webinar wird im Investorenbereich der Curis-Website verfügbar sein, mit einer späteren Wiederholung auf www.curis.com.
- None.
- None.
Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast can be accessed here from the investor section of the Curis website. A replay of the conference call will be available at www.curis.com.
About Curis, Inc.
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS) with either a FLT3 mutation or a splicing factor mutation (U2AF1 or SF3B2), and as a frontline combination therapy with azacitidine and venetoclax in patents with AML. Emavusertib has received Orphan Drug Designation from the
View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-report-second-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-august-1-2024-302206055.html
SOURCE Curis, Inc.
FAQ
When will Curis (CRIS) report its Q2 2024 financial results?
How can investors participate in Curis's (CRIS) Q2 2024 earnings call?
What is the main product Curis (CRIS) is developing?
Where can investors find a replay of Curis's (CRIS) Q2 2024 earnings call?
